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A B S T R A C T
Introduction: The increased radioresistance of hypoxic cells compared to well-oxygenated cells is quantified by
the oxygen enhancement ratio (OER). In this study we created a FLUKA Monte Carlo based tool for inclusion of
both OER and relative biological effectiveness (RBE) in biologically weighted dose (ROWD) calculations in
proton therapy and applied this to explore the impact of hypoxia.
Methods: The RBE-weighted dose was adapted for hypoxia by making RBE model parameters dependent on the
OER, in addition to the linear energy transfer (LET). The OER depends on the partial oxygen pressure (pO2) and
LET. To demonstrate model performance, calculations were done with spread-out Bragg peaks (SOBP) in water
phantoms with pO2 ranging from strongly hypoxic to normoxic (0.01–30 mmHg) and with a head and neck
cancer proton plan optimized with an RBE of 1.1 and pO2 estimated voxel-by-voxel using [18F]-EF5 PET. An RBE
of 1.1 and the Rørvik RBE model were used for the ROWD calculations.
Results: The SOBP in water had decreasing ROWD with decreasing pO2. In the plans accounting for oxygenation,
the median target doses were approximately a factor 1.1 lower than the corresponding plans which did not
consider the OER. Hypoxia adapted target ROWDs were considerably more heterogeneous than the RBE1.1-
weighted doses.
Conclusion: We realized a Monte Carlo based tool for calculating the ROWD. Read-in of patient pO2 and esti-
mation of ROWD with flexibility in choice of RBE model was achieved, giving a tool that may be useful in future
clinical applications of hypoxia-guided particle therapy.
1. Introduction
Cells with partial oxygen pressure (pO2) lower than 8–10 mmHg are
generally termed hypoxic [1] and are more radioresistant than cells
with normal oxygen levels (pO2 up to around 100 mmHg [1]). This
effect may be quantified by the oxygen enhancement ratio (OER),
which is the ratio of the dose at a given oxygen pressure to that at a
normal oxygen pressure producing the same biological effect. The OER
is comparable for photons and protons, but decreases at low proton
energies where the linear energy transfer (LET) is higher [2]. This effect
is more pronounced for heavier particles such as carbon ions. In
radiotherapy treatment planning, the local dose should ideally reflect
the oxygen levels to minimize radiation exposure while remaining ef-
fective. Furthermore, the relative biological effectiveness (RBE) is
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applied to transfer clinical treatment protocols from photon therapy to
proton therapy. This is currently implemented by delivering a homo-
geneous RBE-weighted dose to the target, with the RBE set to 1.1 [3].
However, the RBE is known to vary and several RBE models at nor-
moxic conditions have been proposed [4–7]. To account for the varying
oxygen levels and the variable RBE in particle therapy, a common
framework for combing the effects in RBE and OER weighted dose
(ROWD) calculations could improve the patient treatment outcome.
A common method of measuring the pO2 in vivo is by invasive
oxygen-sensitive electrodes. However, such methods are limited to ac-
cessible tissues and does not give a full three-dimensional representa-
tion of the pO2 levels in the patient [8]. With functional imaging such as
positron emission tomography (PET) or magnetic resonance imaging,
information about the oxygen level can be obtained on a voxel-by-voxel
basis [9]. Several methods for depicting hypoxia with functional ima-
ging have been proposed, and PET is currently the preferred modality
when studying hypoxia in clinical settings [10]. Among the tracers in
clinical use, two hypoxia radiotracers for PET are 18F-fluor-
omisonisazole ([18F]-FMISO) and 18F-labeled 2-(2-nitro-1H-imidazol-1-
yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide ([18F]-EF5). While
[18F]-FMISO is the most actively investigated hypoxia PET tracer, [18F]-
EF5 has the advantage that the non-labeled form of this compound has
been widely used to study hypoxia in clinical and preclinical settings.
Moreover, the hypoxia-avidity of this tracer has been demonstrated
convincingly [11–13]. Also, EF5 binding in hypoxic head-and-neck
squamous cell cancer is rather well established and has been shown to
relate with poor outcome in photon radiochemotherapy [14,15].
Monte Carlo (MC) simulations are frequently used to provide esti-
mates of the RBE-weighted dose in proton and carbon ion therapy, and
several RBE models which do not account for hypoxia have already
been implemented in the FLUKA MC code [16,17]. This includes the
local effect model (LEM) [18,19] and the microdosimetric kinetic
model (MKM) [20,21], whereas several methods for accounting for
both RBE and hypoxia in particle therapy treatment planning have been
suggested [22–25]. Scifoni et al. [23] and Tinganelli et al. [25] de-
scribed a ROWD optimization algorithm incorporating OER (through a
semiempirical model) and RBE (using LEM IV), and implemented this
into the analytical treatment planning system (TPS) TRiP98 [26,27].
They applied an OER model which was intended for particle therapy
with heavier ions like carbon and oxygen. For protons, the same ROWD
estimation method can be applied, however, an OER model developed
specifically for protons would be more suitable, as the universal OER
models may overestimate the OER for protons [2]. Wenzl and Wilkens
[28] developed an OER model with parameters which depend on the
LET and the pO2, which was based on experimental data from several
types of particles, including, but not limited to, protons and carbon
ions. To our knowledge, none of the currently available OER models
have parameters based on proton data only, although Strigari et al. [24]
included a particle dependency in their calculation of the OER. In this
study we developed a method for recalculating treatment plans with a
ROWD, with flexibility regarding the choice of RBE model, and im-
plemented the method in the FLUKA MC code. This will indicate po-
tential areas of lower tumor dose effect in a volume with varying degree
of hypoxia. Including the method in the dose optimization process
would then enable delivering a homogeneous ROWD, i.e. equal biolo-
gical effect across regions with different oxygen levels.
2. Materials and methods
2.1. Estimation of oxygen levels in a patient
The patient oxygen levels, given as pO2, were estimated using PET
images of head and neck cancer patients with [18F]-EF5 as hypoxia
tracer. The PET images were acquired between 2013 and 2016 using a
GE D690 PET/CT scanner (General Electric Medical Systems,
Milwaukee, WI, USA) at Turku University Hospital (Finland) [29]. The










where A, B and C are reaction-specific parameters [30]. We estimated
these parameters for [18F]-EF5 PET by non-linear least square curve fit
of the uptake data from PET images of six head and neck cancer patients
in organs with pO2 values reported in literature, see Appendix A for
details. The PET uptake was normalized to mean muscle uptake, as a
tumor-to-muscle (T/M) ratio of 1.5 at 3 h from injection has been found
to be an appropriate threshold for determining clinical significant hy-
poxia in [18F]-EF5 PET images [13].
2.2. Calculations of oxygen enhancement ratio
The OER was calculated applying a version of the model by Wenzl
and Wilkens [28], modified by obtaining the model coefficients by re-
gression to in vitro proton data only. The Wenzl and Wilkens [28] OER
model calculates the survival fraction of cells, S, after ion irradiation
according to the linear quadratic (LQ) model [31]:
= +S D Dln( ) ,2 (2)
where D is the physical dose. and are the radiosensitivity para-
meters, defined by Wenzl and Wilkens [28] as follows:
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where L is the dose-averaged LET (LETd), p is the pO2, and K is set to
3 mmHg [28]. By non-linear least square curve fit of in vitro proton data
(Fig. 1 and Table B.1 in Appendix B) the model parameters were found
to be: a1 = 0.10 Gy−1, a2 = 0.0010 µm/(Gy·keV), a3 = 0.010 Gy−1,
a4 = 0.0100 µm/(Gy·keV), b1 = 0.765 Gy-1and b2 = 0.273 Gy−1 (see
Appendix B for details). From this, the OER can be calculated:
=L p
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where ph and pa are the oxygen pressure at the hypoxic and aerobic (or
normoxic) conditions, respectively. In our implementation ph was
Fig. 1. In vitro proton data at 10% cell survival (stars) and OER calculations
done according to Eq. (5), with pa = 160 mmHg and ph = 0.01 mmHg (lines).
The blue line is obtained by non-linear least square curve fit to the proton data
(stars), while the black line applies parameters given by Wenzl and Wilkens
[28] (given in Table B.2. Appendix B), obtained by fitting to data from several
different ions. See Appendix B for details on the proton in vitro data. (For in-
terpretation of the references to colour in this figure legend, the reader is re-
ferred to the web version of this article.)
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obtained from the PET image and we set pa equal to 30 mmHg as this is
a typical pO2 value for tissues [28]. This value for pa is lower than what
is given in Fig. 1. Fig. 1 applies the aerobic condition in in vitro ex-
periments, which is generally fixed to 160 mmHg and higher than what
is normally found in vivo [28]. As the model parameters are based on a
survival fraction of 10%, we also set the survival level to 10% in our
calculations.
2.3. RBE-weighted dose calculations for normoxic conditions
To adapt the RBE-weighted dose for hypoxia, a short description of
RBE calculations for normoxic conditions is needed. For a more thor-
ough description, see Rørvik et al. [32]. In general, the RBE is calcu-



















where Dp is the physical proton dose deposited per fraction and αa, βa,
αx and βx are the normoxic proton and photon radiosensitivity para-
meters, respectively. The various RBE models differ in how these
radiosensitivity parameters are defined [32]. We applied two methods
to calculate the RBE, as described below.
In the first method, the RBE-weighted dose (DRBE1.1) was calculated
using a constant RBE of 1.1. To achieve this using Eq. (6), which is
required to later include the OER in the calculations, we used the same
radiosensitivity parameters for photons and protons, i.e. =a x and
=a x . This would give the same survival curve for protons and pho-
tons, and thus an RBE of 1. The DRBE1.1 is then given by Eq. (6) mul-





















where =a x and =a x, and are given as in the previously described
OER model (Eqs. (3) and (4)), with a pO2 value set to 30 mmHg and a
constant LETd of 0.3 keV/µm.
In the second method, the RBE-weighted dose (DROR) was estimated
applying the variable RBE model by Rørvik et al. [5] (see Appendix C
for details). We applied an ( / )x = 2 Gy for all structures. However,
published ( / )x ratios for head and neck cancer vary significantly, and
when applying the tool for further testing, a larger range of ( / )x ratios
should be applied [33]. As the goal here was to demonstrate the
method, we chose a ( / )x ratio representing organs at risk (OARs) and
late responding target volumes which have low ( / )x values [32].
2.4. RBE and OER weighted dose calculations
To account for hypoxia in the calculations of ROWD, we have, si-
milar to Scifoni et al. [23] and Tinganelli et al. [25], replaced the
normoxic proton response parameters in Eq. (6) with hypoxic proton
response parameters which vary with the OER:
= L p/OER( , ),h a h (8)
= L p/OER ( , ),h a h2 (9)
where the OER is the OER at 10% cell survival calculated according to
Eq. (5). This ROWD model allows us to apply a, a, x and x as defined
in most of the existing RBE models derived from normoxic proton and
photon in vitro data and then estimate h and h applying Eqs. (8) and


















where D is the total deposited physical dose and Dp is the physical dose
deposited by protons only. While this ROWD model will give an iso-
effective dose accounting for hypoxia, we called it DOER,RBE to empha-
size that it is not directly the RBE-weighted dose, as only the proton
parameters take hypoxia into account and not the photon parameters.
The x and x parameters are always the normoxic photon radio-
sensitivity parameters.
The DRBE1.1 and the DROR models were adapted to variable oxygen
levels by changing their respective a and a parameters to h and h
according to Eqs. (8) and (9), and keeping x and x as defined in each
model. To distinguish the models adapted for hypoxia and not adapted
for hypoxia, the models adapted for hypoxia will hereafter be referred
to as DOER,RBE1.1 and DOER,ROR.
2.5. Implementation of the method in FLUKA
Our in-house made system [34] for recalculating treatment plans in
FLUKA was modified to include the hypoxia inclusive ROWD calcula-
tion method. This tool translates DICOM information from a treatment
plan generated in an analytical TPS to files readable by FLUKA. This
includes information on the radiation beam and scrips translating the
CT image into FLUKA geometry. When simulating a treatment plan, we
scored LETd, pO2, physical dose D, Da and Da in FLUKA. The OER
was then calculated in Python according to Eq. (5), using LETd, pO2 and
D from FLUKA, and the ROWD was subsequently calculated using Eq.
(10).
LETd, Da , Da and pO2 were scored using the FLUKA subroutine
fluscw (FLUence Scoring Weight). LETd was here estimated applying the
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where E( )i is the fluence of particle species i with kinetic energy E and
ELET ( )i is the unrestricted LET for the same kinetic energy. To score
pO2, we implemented a method for importing estimated pO2 values in a
patient geometry on a voxel-by-voxel basis in FLUKA using fluscw. This
subroutine reads the pO2 values from a table, created from the PET
images; the coordinate system of the PET image was converted into
FLUKA coordinates, and for each particle position, the corresponding
pO2 value from the PET image was given. Subsequently, pO2 times dose
to water and dose to water were scored in FLUKA. Then, pO2 was given
by the quotient of the two scored quantities. To achieve the needed
accuracy of the scored values without increasing the simulation time
significantly, we set the fraction of the kinetic energy to be lost in a
simulation step to 0.0125, which was 25% of the default value when
applying the FLUKA HADROTHErapy defaults.
2.6. Treatment plans
Two spread-out Bragg peak (SOBP) scenarios in water and a treat-
ment plan for head and neck cancer were used to test the MC tool and
investigate the impact of hypoxia on ROWD estimations. The treatment
plans were optimized using an RBE of 1.1 in the Eclipse (Varian Medical
Systems, Palo Alto, CA, USA) TPS, not accounting for hypoxia, and then
recalculated to account for hypoxia and RBE using our FLUKA based
tool. For all simulations, the number of simulated primary particles was
chosen to have a voxel mean statistical uncertainty< 2%.
The first SOBP scenario had the same dimensions as the pO2 table,
with scoring voxels of (1.95 × 1.95 × 2.4 mm3). This SOBP scenario
was only used to check the FLUKA estimation of pO2 values. The second
SOBP scenario (starting at depth 8 cm and with size 4 × 4 × 4 cm3)
was optimized to an DRBE1.1 dose of 2 Gy(RBE) and applied in four
simulated water phantoms. Each simulated water phantom had
homogeneously distributed pO2 values, with each of the four phantoms
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having a given pO2: 0.01 mmHg, 0.5 mmHg, 3.0 mmHg or 30.0 mmHg.
The simulated phantoms had scoring voxels of same size as in the TPS
(2 × 2 × 2 mm3).
The head and neck cancer patient was originally treated at Turku
University Hospital with chemoradiotherapy [29], and the PET images
of this patient were included in creating the PET uptake to pO2 con-
version curve (Appendix A). For this study, we created a proton treat-
ment plan for the patient, optimized (using an RBE of 1.1) in the Eclipse
TPS with prescribed dose of 70 Gy(RBE) in 35 fractions to the planning
target volume (PTV). pO2 values of the patient were estimated from
[18F]-EF5 PET/CT images of the patient, and the FLUKA scoring was
done using the same grid and voxel size (1.95 × 1.95 × 2.50 mm3) as
used during the TPS optimization.
3. Results
3.1. FLUKA readout of pO2
The generated pO2 map was successfully read by FLUKA, as shown
in Fig. D.1 in Appendix D. The process of importing patient pO2 data in
FLUKA started with a [18F]-EF5 PET image (Fig. D.1a). The conversion
from PET uptake to pO2 was done applying Eq. (1) with reaction-spe-
cific parameters found to be A = 2.60, B = 1.98 and C = 2.5 mmHg,
see Appendix A for details. The estimated pO2 table (Fig. D.1b) corre-
sponding to the PET image showed areas of low pO2 values in the PTV,
with minimum, mean and maximum pO2 in the PTV of 2.2, 16.8 and
60.0 mmHg, respectively. This was also reproduced by the FLUKA
imported pO2 values (Fig. D.1c).
3.2. Water phantom
Compared to DRBE1.1, the ROWD accounting for hypoxia decreased
with decreasing pO2 values, as seen in Fig. 2. The decrease rate typi-
cally followed the factors corresponding to the OER values for re-
spective oxygenation levels in Fig. 2. This shows that the proton irra-
diation is predicted to be less effective at low oxygen levels, as expected
from the definition of the OER. At 30 mmHg, which is a normoxic
condition, the DOER,RBE1.1 dose was equal to the prescribed dose, as
expected. Applying the DOER,ROR model, however, an RBE of 1.09 was
observed at the beam entrance, increasing to 1.38 at the distal end of
the beam, at normoxic condition. For all oxygen levels, the OER value
was seen to be mostly constant along the beam path, with a slight de-
crease at high LETd values. This decrease was most significant at low
oxygen levels. At 0.01 mmHg, which is an extremely hypoxic condition,
the OER value started at 2.7 for low LETd values and decreased to 2.3 at
the end of the beam range.
3.3. Patient case
The pO2 map of the head and neck cancer patient is shown in
Fig. 3a. The treatment plan had LETd values in the range of
1.2–4.3 keV/µm in the PTV (Fig. 3b). The dose volume histograms
(DVHs) of the DRBE1.1, DROR, DOER,RBE1.1 and DOER,ROR are shown in
Fig. 3c. The DROR model gave the largest dose to the PTV, and the
DRBE1.1 the second largest dose, except in 18% of the volume where the
DOER,ROR had larger dose, as DOER,ROR gives the same dose as the DROR
model in the normoxic parts of the PTV. The normoxic RBE-weighted
doses (DRBE1.1 and DROR) had the steepest DVHs, which was also re-
flected in the dose distributions shown in Fig. 3d–f, where a homo-
genous DRBE1.1 to the PTV was observed, while the ROWDs accounting
for hypoxia had areas with clearly lower dose. The corresponding DROR
distribution is given in Fig. 4, showing also a mainly homogeneous dose
distribution to the PTV.
The median target dose (D50%), with the range from the near
minimum target dose (D98%) to the near maximum target dose (D2%) in
parenthesis, was 69.9 Gy(RBE) (62.8–74.3 Gy(RBE)), 62.6 Gy(RBE)
(52.6–73.9 Gy(RBE)), 74.0 Gy(RBE) (65.3–78.9 Gy(RBE)) and 66.5 Gy
(RBE) (56.8–78.9 Gy(RBE)) when estimated applying DRBE1.1,
DOER,RBE1.1, DROR and DOER,ROR, respectively. The dose difference be-
tween DRBE1.1 and DOER,RBE1.1 is given in Fig. 3g, showing even clearer
that low oxygen levels result in lower biological effect of the radiation,
as expected. This is also seen in Fig. 4, where the DROR-DOER,ROR dose
difference is given, showing that the differences DROR-DOER,ROR and
DRBE1.1-DOER,RBE1.1 are comparable. The similar shapes of the dose dif-
ference can be attributed to the approximately homogeneous LETd and
physical dose distribution in the target.
4. Discussion
In this study we developed a tool for calculating the ROWD in hy-
poxic conditions for protons, by coupling the FLUKA MC code with a
ROWD calculation model. The tool was tested with simple treatment
plans for homogeneous water phantoms with several oxygen levels as
well as on a head and neck cancer patient plan with pO2 estimated from
[18F]-EF5 PET images. Applying a method based on the LQ model has
several benefits, one being that the RBE effects are also directly in-
cluded in the calculations. Such calculations may become useful in
future clinical applications of hypoxia-guided particle therapy.
Scifoni et al. [23] and Tinganelli et al. [25] accounted for hypoxia
applying the same approach as in the current work, by using the LEM
and a dedicated OER model implemented in the TRiP98 TPS, which
facilitated RBE and OER driven optimization (kill painting). Wouters
and Brown [35], and later Malinen et al. [36], also applied this form-
alism to estimate hypoxic α and β values from normoxic α and β
Fig. 2. RBE and OER weighted dose estimated applying the DOER,RBE1.1 model (a) and the DOER,ROR model (b), and estimated OER (c) as a function of depth for several
oxygen levels. LETd as a function of depth is also included in the plots.
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parameters. Using this approach, the physical dose is weighted by the
inverse of the OER before calculating the RBE. Due to the dose de-
pendency of a variable RBE, the RBE will therefore be slightly depen-
dent on the OER. The estimated ROWD is therefore not equal to the
RBE-weighted dose divided by the OER, but the difference is small.
We applied our tool using the variable RBE model by Rørvik et al.
[5], in addition to a constant RBE of 1.1. The tool could also be applied
on most other normoxic proton RBE models, as well as RBE models for
heavier ions, which follow the general RBE equation (Equation (6)).
The OER model used in this study was based on the model by Wenzl and
Wilkens [28], but with model parameters estimated from proton in vitro
data only, as the OER has been seen to decrease significantly faster with
the LETd when applying low-LET irradiation compared to high-LET ir-
radiation, especially towards the end of the particle range [2]. Strigari
et al. [24] observed this same trend, i.e. the lighter the particles the
faster the OER decreases with increasing LET, when computing OER vs.
LET curves for different particle types. This was also observed in our
study, as the OER decreased faster when applying proton parameters
than when applying parameters based on the data for several ion types
(Fig. 1). When applying the tool to high-LET radiation, e.g. carbon ions,
the OER model parameters must be adjusted to data taken from heavier
ions, for instance using the parameters given by Wenzl and Wilkens
[28].
The Wenzl and Wilkens [28] OER model has been seen to deviate
from other existing OER models, resulting in lower OER for low LET
radiation compared to the models by Scifoni et al. [23], Strigari et al.
[24] and Antonovic et al. [37]. However, this may be due to the opti-
mization of the model parameters [24]. For instance, using the model
parameters in the Wenzl and Wilkens [28] OER model one assumes that
all hypoxic in vitro data has a controlled pO2 of 0.01 mmHg. To tune the
existing OER models and judge which one is best, more experimental
data is required. To reduce the uncertainty in experimental OER data, it
is necessary to estimate LET values accurately and consistently between
experiments, preferably using Monte Carlo simulations of the irradia-
tion setup [38,39]. In addition, as the OER is dependent on the tissue
type, there may be differences between the clinical OER and the in vitro
OER, which may influence the results since the OER model parameters
are generally based on in vitro data. However, Wenzl and Wilkens [28]
Fig. 3. pO2 map (a), LETd (b), PTV dose volume histograms (c), DRBE1.1 (d), DOER,RBE1.1 (e), DOER,ROR (f) and dose difference between DRBE1.1 and DOER,RBE1.1 (g). The
PTV is delineated in pink. All calculations have been done in FLUKA, applying a dose plan optimized to an RBE of 1.1 in Eclipse. To save simulation time, only pO2
values inside and directly around the PTV was included in the table, while outside the table the pO2 was set to 60 mmHg. The pO2 and LETd in voxels receiving doses
below 0.7 Gy(RBE) according to the DRBE1.1 dose (1% of prescription dose) is set transparent.
Fig. 4. DROR (a), DOER,ROR (b) and dose difference between DROR and DOER,ROR (c). PTV is delineated in pink. All calculations have been done in FLUKA, applying a
dose plan optimized to an RBE 1.1 in Eclipse.
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showed that there was generally good agreement between their OER
model and results from preclinical and clinical studies (mainly per-
formed applying photon irradiation). We therefore decided to use this
model in our calculations, although uncertainties in the OER model
must be acknowledged.
In the current OER model, the parameters were designed for a cell
survival of 10%, ignoring a possible dose dependency. Wenzl and
Wilkens [40] studied this dependency and found that the OER did not
vary significantly with the dose, especially at high LET values and high
pO2 values. At lower LET values there was a clear dose dependency, but
this was most pronounced for extremely hypoxic cells with lower pO2
than what was seen in our patient case. The dose dependency also
differed significantly between different cell lines. We therefore chose to
maintain the survival level at 10% in our calculations, even though this
may be a minor shortcoming. To extend the model to other survival
levels, more experimental data is needed to fit the model parameters.
Scifoni et al. [23] and Tinganelli et al. [25] did also ignore the dose
dependency of the OER, although justified as their method was applied
to high LET radiation.
The MC tool presented in this study depends on estimations of the
pO2 levels in a patient on a voxel-by-voxel basis. As our main objective
was to demonstrate the tool performance, the pO2 estimates should be
regarded as an approximation in order to provide an indication of how
pO2 values will influence clinical scenarios. Toma-Dasu et al. [30] as-
sumed that PET uptake as a function of pO2 follows a sigmoid shaped
curve, as the inhibition of chemical reactions typically follows this
form. They showed their method for [18F]-FMISO PET and [18F]-FETA
PET. While these tracers are, just like [18F]-EF5, nitroimidazole tracers,
it is not certain that the conversion from [18F]-EF5 uptake to pO2 fol-
lows exactly this form, as different radiotracers have different uptake
properties and with that different capabilities of imaging pO2 [30]. This
method has also been applied for other PET tracers, including [18F]-
HX4 PET [41]. While uncertainties are expected, the pO2 conversion
curve was only applied to the tumor area and its proximity to save
simulation time, and the pO2 of the remaining tissue was set to
60 mmHg. Thus, uncertainties in pO2 estimation will not have sig-
nificant impact on the dose to the normal tissue. Also, the lowest pO2
value in the tumor applied in this study was estimated to be 2.2 mmHg,
which corresponds to an OER of approximately 1.6. If the conversion
curve (Appendix A, Fig. A.1) was less steep, as the data may suggest,
this OER value would be an underestimation. An underestimation may
not give high enough dose escalation to the tumor; however, it will be
safer for the normal tissue.
The method to account for hypoxia in our study is, as mentioned,
similar to the one on which the kill painting algorithm is based [23,25].
Kill painting was first proved experimentally, using cell exposure
chambers which allow irradiating of cell cultures under defined oxy-
genation conditions [23,25]. Later, kill painting was applied in a
treatment planning study with TRiP98 and an artificially generated
[18F]-FMISO-PET derived hypoxia map of a patient [42]. In addition to
this method, hypoxia has earlier also been accounted for in treatment
planning studies applying dose and/or LET painting, i.e. where the
hypoxic volumes receive either increased dose and/or increased LET
values, respectively [43–45]. Malinen and Søvik [43] found that hy-
poxia dose painting appeared to be especially attractive for protons,
while both LET and dose painting has the potential to increase the
tumor control probability for heavier ions like lithium and carbon.
Chang et al. [46] also studied dose painting and showed that dose
painting in conventional radiotherapy based on [18F]-FMISO PET is
technically feasible and has clear benefits in terms of increasing the
tumor control probability. Kjellsson Lindblom et al. [41] showed, in
addition, that dose painting in photon therapy based on [18F]-HX4 PET
appears feasible in non-small cell lung cancer. Our tool does not yet
include optimization of treatment plans based on the oxygenation le-
vels; however, future work includes implementing the method in a
FLUKA Monte Carlo based treatment planning system.
5. Conclusion
The Monte Carlo based tool introduced in this study facilitates the
determination of potential regions with underdosage in a tumor due to
hypoxia. By further implementing the method in a treatment planning
tool, it will be possible to adapt prescription doses based on the local
tumor oxygen level, also accounting for RBE effects through coupling
with existing RBE models. The resulting biologically weighted dose at a
hypoxic condition compared to that in a normoxic condition was lower
by a factor similar to the OER. For the head and neck cancer patient,
this resulted in large areas of underdosage compared to the prescribed
dose. While variable normoxic RBE models generally estimate higher
biologically weighted dose than the DRBE1.1, areas of underdosage were
also observed when applying the DROR model adapted for hypoxia in
biologically weighted dose estimations. The results in this study con-
firm that neglecting the effect of hypoxia in proton therapy potentially
could compromise the expected tumor control probability and should
therefore be kept in mind in clinical practice.
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